Edition:
United States

Mabion SA (MABP.WA)

MABP.WA on Warsaw Stock Exchange

116.00PLN
23 Feb 2018
Change (% chg)

2.00zł (+1.75%)
Prev Close
114.00zł
Open
113.00zł
Day's High
123.80zł
Day's Low
113.00zł
Volume
3,183
Avg. Vol
5,942
52-wk High
139.00zł
52-wk Low
81.26zł

Latest Key Developments (Source: Significant Developments)

Mabion Q3 Net Loss Narrows To 13.2 Million Zlotys
Thursday, 30 Nov 2017 01:46am EST 

Nov 30 (Reuters) - MABION SA ::SAID ON WEDNESDAY THAT ITS Q3 NET LOSS WAS 13.2 MILLION ZLOTYS VERSUS LOSS OF 14.4 MILLION ZLOTYS.  Full Article

Mabion to get 28 mln zloty subsidy for biotech medicine development
Thursday, 5 Oct 2017 03:56am EDT 

Oct 5 (Reuters) - MABION SA ::SAID ON WEDNESDAY THAT NATIONAL CENTRE FOR RESEARCH AND DEVELOPMENT IN POLAND HAS SIGNED THE CONTRACT TO FINANCE THE COMPANY'S PROJECT FOR DEVELOPMENT OF A BIOTECH MEDICINE .THE SUBJECT OF THE PROJECT IS TO CARRY OUT R&D WORKS AIMED AT DEVELOPING MABIONEGFR - MONOCLONAL ANTIBODY WITH THE POTENTIAL OF THE MEDICINAL PRODUCT FOR USE IN ONCOLOGIC INDICATIONS .THE TOTAL VALUE OF THE PROJECT AMOUNTS TO 40 MILLION ZLOTYS AND THE SUBSIDY VALUE AMOUNTS TO 28 MILLION ZLOTYS.  Full Article

Mabion Q2 net loss narrows to 12.5 mln zlotys
Monday, 18 Sep 2017 03:57am EDT 

Sept 18 (Reuters) - MABION SA ::SAID ON FRIDAY THAT Q2 OPERATING LOSS WAS 14.6 MILLION ZLOTYS VERSUS LOSS OF 13.6 MILLION ZLOTYS YEAR AGO.Q2 NET LOSS WAS 12.5 MILLION ZLOTYS VERSUS LOSS OF 13.8 MILLION ZLOTYS YEAR AGO .  Full Article

Mabion Q1 net loss widens to 12.9 mln zlotys
Tuesday, 30 May 2017 01:05am EDT 

May 30 (Reuters) - MABION SA ::REPORTED ON MONDAY Q1 OPERATING LOSS AT 14.4 MILLION ZLOTYS VERSUS LOSS OF 10.1 MILLION ZLOTYS A YEAR AGO .Q1 NET LOSS WAS 12.9 MILLION ZLOTYS VERSUS LOSS 10.1 MILLION ZLOTYS A YEAR AGO .  Full Article

Mabion Q1 prelim. net loss at 16 mln zlotys
Thursday, 11 May 2017 04:15am EDT 

May 11 (Reuters) - MABION SA ::SAID ON WEDNESDAY THAT ITS Q1 PRELIM. NET LOSS WAS AT 16 MILLION ZLOTYS ON REVENUE OF 0 ZLOTYS .ACCORDING TO MABION'S MANAGEMENT, THE SUPPORT FROM SHAREHOLDERS AND LONG-TERM COOPERATION AGREEMENT WITH MYLAN IRELAND LIMITED PROVIDING FINANCING FOR MABIONCD20 JUSTIFIES FURTHER OPERATIONS OF MABION IN LINE WITH ITS DEVELOPMENT STRATEGY .DUE TO THE ESTIMATED LEVEL OF MABION'S OWN CAPITALS THOUGH, AT MINUS 12 MILLION ZLOTYS AS OF MARCH 31, THE MANAGEMENT IS TO PROPOSE VOTING OVER MABION'S FURTHER EXISTENCE AT THE NEXT GENERAL MEETING OF SHAREHOLDERS.THE COMPANY'S FULL Q1 REPORT WILL BE PUBLISHED ON MAY 29.  Full Article

Mabion FY 2016 net loss widens to 55.8 mln zlotys
Wednesday, 26 Apr 2017 03:16am EDT 

April 26 (Reuters) - Mabion SA ::Informed on Tuesday that its FY 2016 revenue was 0 zlotys versus 2.7 million zlotys ($697,566) a year ago.FY 2016 operating loss was 55.5 million zlotys versus loss of 42.1 million zlotys a year ago.FY 2016 net loss was 55.8 million zlotys versus loss of 42.5 million zlotys a year ago.  Full Article

Mabion FY 2016 net loss increases by 44.2 mln zlotys following changes in accounting policy
Monday, 24 Apr 2017 11:19am EDT 

April 24 (Reuters) - Mabion SA ::The company's FY 2016 net loss increases by 44.2 million zlotys ($11.33 million) following changes in accounting policy.  Full Article

Mabion EGM resolves to increase capital via issue up to 4.5 mln shares
Thursday, 16 Feb 2017 09:10am EST 

Mabion SA : Its extraordinary general meeting of shareholders (EGM) resolves to issue up to 4.5 million shares of nominal value of 0.1 zloty ($0.0247) per share . 4.0 million shares to be issued via public offer to investors outside of Poland .500,000 shares to be issued via private subscription in Poland.  Full Article

DSMB positively assesses Mabion's comparative study of MabionCD20 drug
Friday, 23 Dec 2016 04:21am EST 

Mabion SA : Said on Thursday that Data and Safety Monitoring Board (DSMB) assessed clinical data and safety data obtained from patients in comparative study of the drug MabionCD20 and the MabThera reference product (MabThera) . After the evaluation reports on the general course of the clinical trial and other presented data on safety and efficacy DSMB positively assessed the conduct of the company's study and recommended its further running without having to make changes in the protocol . Company said adverse drug reactions observed in a clinical study in any of the two groups of patients did not differ significantly neither in the scope nor the severity from the typical side effects of treatment with MabThera . Said this may suggest that regulatory risk in terms of the safety profile of MabionCD20 compared to MabThera decreased . DSMB examined data obtained from 561 patients on March 28 and raw data obtained from additional 148 patients between March 28 and Dec. 21 .As of Dec. 21, all 709 patients received all the drug doses under the research protocol and the drop out under the research is 11.16 pct, lower than expected.  Full Article

Mabion Q3 net loss increases to 6.5 mln zlotys YOY
Wednesday, 16 Nov 2016 03:52am EST 

Mabion SA : Reported on Tuesday Q3 net loss of 6.5 million zlotys ($1.57 million) versus 4.3 million zlotys a year ago .Said its management board decided to withdraw the company's financial forecasts published in 2010, decided not to publish financial forecasts.  Full Article

BRIEF-Mabion Files For Patent For Its Therapy Of Multiple Sclerosis

* FILES FOR PATENT FOR ITS INVENTION 'COMBINATION THERAPY OF MULTIPLE SCLEROSIS COMPRISING A CD20 LIGAND' Source text for Eikon: Further company coverage: (Gdynia Newsroom)